# Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

> **NCT06057571** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **TransThera Sciences (Nanjing), Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Cholangiocarcinoma Metastatic

## Interventions

- **DRUG:** TT-00420 (tinengotinib)

## Key facts

- **NCT ID:** NCT06057571
- **Lead sponsor:** TransThera Sciences (Nanjing), Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-17
- **Primary completion:** 2025-07-27
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057571, "Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06057571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*